A Phase 3 interventional study of RAY1225 and placebo in T2DM, sponsored by Guangdong Raynovent Biotech Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-24.
Sponsored by Guangdong Raynovent Biotech Co., Ltd (part of Guangdong Zhongsheng Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal for this study is to evaluate the efficacy and safety of RAY1225 versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
Guangdong Raynovent Biotech Co., Ltd is the lead sponsor of 36 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 3 milligrams (mg) of RAY1225 as subcutaneous injection once every two week.
Drug: RAY1225
Participants received 6 milligrams (mg) of RAY1225 as subcutaneous injection once every two week.
Drug: RAY1225
Participants received 9 milligrams (mg) of RAY1225 as subcutaneous injection once every two week.
Drug: RAY1225
Participants received placebo as subcutaneous injection once every two week.
Drug: placebo
Administered SC
Administered SC
Change From Baseline in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A.
Time frame: Baseline,36 Week
Percentage of Participants Achieving an HbA1c Target Value of <7%
Time frame: Baseline,36 Week
Percentage of Participants With HbA1c Target Value of <6.5%
Time frame: Baseline,36 Week
Mean change in fasting serum glucose
Time frame: Baseline,36 Week
Proportion of patients who achieved weight loss of >5%, >10%, and >15% from baseline
Time frame: Baseline,36 Week
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Dec 2026, 15 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bilpatide
Guangdong Raynovent Biotech Co., Ltd →